We are always very transparent about the pharmacies that we use, and we have good relationships with our pharmacies
Newer options are also advancing quickly, and you can see where the science is heading in what the latest retatrutide trial data suggests
Industry publications framed the event in stark terms, with one headline reading, Skye Bioscience stock plummets after failed weight loss drug trial. SEC Filings & Risk Factors Skye's 2024 10-K (March 20, 2025) disclosed standard biotech perils: "Clinical trials may fail to demonstrate safety and efficacy," with specifics on nimacimab's Phase 2 uncertainties, including "potential for suboptimal dosing" and "failure to meet endpoints." Yet plaintiffs argue these were boilerplate, omitting known gaps in preclinical-to-clinical translation
Potential biomaterials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder: multiple sclerosis
I mean, I dont want to look back when Im 95 years old and say, Okay, I made more money than this person, this person, and this person